Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Exelixis ( (EXEL) ) just unveiled an update.
On November 4, 2025, Exelixis announced a stock repurchase program of up to $750 million to be completed by the end of 2026. The company reported strong financial results for the third quarter of 2025, with total revenues of $597.8 million and significant growth in its cabozantinib franchise. Exelixis also highlighted progress in its clinical trials and pipeline development, including positive results from the STELLAR-303 trial. The company is undergoing a corporate reorganization plan, which includes workforce changes and office closures, expected to be completed by the end of 2025.
The most recent analyst rating on (EXEL) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Exelixis stock, see the EXEL Stock Forecast page.
Spark’s Take on EXEL Stock
According to Spark, TipRanks’ AI Analyst, EXEL is a Outperform.
Exelixis’s overall stock score is driven by its strong financial performance and positive earnings call sentiment, highlighting robust revenue growth and strategic advancements in oncology. The technical analysis presents a mixed outlook, while the valuation suggests a fair market price. The absence of corporate events and dividend yield is typical for the industry, focusing on growth and reinvestment.
To see Spark’s full report on EXEL stock, click here.
More about Exelixis
Exelixis, Inc. operates in the biotechnology industry, focusing on the development and commercialization of new medicines to treat cancer. Its primary products include the cabozantinib franchise, with CABOMETYX® being a leading oral therapy for renal cell carcinoma and neuroendocrine tumors. The company is also advancing its pipeline with new drug applications and clinical trials, aiming to improve cancer care standards.
Average Trading Volume: 2,636,369
Technical Sentiment Signal: Buy
Current Market Cap: $10.25B
For an in-depth examination of EXEL stock, go to TipRanks’ Overview page.